[SCHEDULE 13G] Black Diamond Therapeutics, Inc. Passive Investment Disclosure (>5%)
BlackRock reports 6.7% stake in Black Diamond
BlackRock, Inc. reports beneficial ownership of 3,838,590 shares of Black Diamond Therapeutics, Inc. common stock on a Schedule 13G, representing 6.7% of the class.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
BlackRock, Inc. reports beneficial ownership of 3,838,590 shares of Black Diamond Therapeutics, Inc. common stock on a Schedule 13G, representing 6.7% of the class. BlackRock has sole voting power over 3,806,227 shares and sole dispositive power over 3,838,590 shares, with no shared voting or dispositive power. The filing explains that these holdings are attributed to certain BlackRock business units, and that various underlying clients have rights to dividends or sale proceeds, but no single person has an interest in more than five percent of Black Diamond’s outstanding common shares.
Key Figures
Beneficial ownership:3,838,590 sharesPercent of class:6.7%Sole voting power:3,806,227 shares+4 more
7 metrics
Beneficial ownership3,838,590 sharesShares of Black Diamond Therapeutics common stock beneficially owned by BlackRock
Percent of class6.7%Portion of Black Diamond Therapeutics common stock class held by BlackRock
Sole voting power3,806,227 sharesShares for which BlackRock has sole power to vote or direct the vote
Shared voting power0Shares for which BlackRock has shared power to vote or direct the vote
Sole dispositive power3,838,590 sharesShares for which BlackRock has sole power to dispose or direct disposition
Shared dispositive power0Shares for which BlackRock has shared power to dispose or direct disposition
Ownership thresholdMore than 5%Schedule 13G filing triggered by holding over 5% of the class
Key Terms
beneficially owned, sole voting power, sole dispositive power, Schedule 13G, +1 more
5 terms
beneficially ownedfinancial
"this reflects the securities beneficially owned, or deemed to be beneficially owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole voting powerfinancial
"Sole Voting Power 3,806,227.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
sole dispositive powerfinancial
"Sole Dispositive Power 3,838,590.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
Schedule 13Gregulatory
"In accordance with SEC Release No. 34-39538 this Schedule 13G reflects"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
parent holding companyregulatory
"Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Black Diamond Therapeutics (BDTX) does BlackRock own?
BlackRock reports beneficial ownership of 6.7% of Black Diamond Therapeutics’ common stock, representing 3,838,590 shares as disclosed in its Schedule 13G filing.
How many BDTX shares does BlackRock have voting power over?
BlackRock has sole voting power over 3,806,227 shares of Black Diamond Therapeutics common stock and no shared voting power, according to the Schedule 13G ownership breakdown.
What dispositive power does BlackRock hold over BDTX shares?
BlackRock has sole dispositive power over 3,838,590 shares of Black Diamond Therapeutics common stock and no shared dispositive power, meaning it alone can direct how those shares are disposed of.
Do any individual BlackRock clients own more than 5% of BDTX?
No. The filing states that while various persons may receive dividends or sale proceeds from BDTX shares, no one person’s interest exceeds five percent of Black Diamond Therapeutics’ total outstanding common shares.
Which entity filed the Schedule 13G for Black Diamond Therapeutics (BDTX)?
The Schedule 13G was filed by BlackRock, Inc., a Delaware corporation, on behalf of certain of its subsidiaries and business units that collectively hold the reported BDTX shares.
What class of BDTX securities is reported in BlackRock’s Schedule 13G?
The Schedule 13G covers common stock of Black Diamond Therapeutics, Inc., identified with CUSIP 09203E105, and details BlackRock’s beneficial ownership in that class.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Black Diamond Therapeutics, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
09203E105
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
09203E105
1
Names of Reporting Persons
BlackRock, Inc.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
3,806,227.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
3,838,590.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,838,590.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.7 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Black Diamond Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
245 First Street, 18th Floor CAMBRIDGE MA 02142
Item 2.
(a)
Name of person filing:
BlackRock, Inc.
In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)
Address or principal business office or, if none, residence:
BlackRock, Inc., 50 Hudson Yards New York, NY 10001
(c)
Citizenship:
See Item 4 of Cover Page
(d)
Title of class of securities:
Common Stock
(e)
CUSIP Number(s):
09203E105
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
3838590
(b)
Percent of class:
6.7 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
3806227
(ii) Shared power to vote or to direct the vote:
0
(iii) Sole power to dispose or to direct the disposition of:
3838590
(iv) Shared power to dispose or to direct the disposition of:
0
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Black Diamond Therapeutics, Inc.. No one person's interest in the common stock of Black Diamond Therapeutics, Inc. is more than five percent of the total outstanding common shares.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See Exhibit 99
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
